Arena Pharmaceuticals, Inc. – Product Pipeline Review – 2012
Summary
Global Market Direct’s pharmaceuticals report, “Arena Pharmaceuticals, Inc. - Product Pipeline Review - 2012” provides data on the Arena Pharmaceuticals, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Arena Pharmaceuticals, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Arena Pharmaceuticals, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
Current R&D Portfolio of Arena Pharmaceuticals, Inc.; Arena Pharmaceuticals, Inc. - Key Therapeutics; Arena Pharmaceuticals, Inc. - Pipeline Overview and Promising Molecules; Arena Pharmaceuticals, Inc. - News; Arena Pharmaceuticals, Inc. - Latest Updates; Arena Pharmaceuticals, Inc. - Pipeline; Arena Pharmaceuticals, Inc. - Discontinued/Dormant Projects
Summary
Global Market Direct’s pharmaceuticals report, “Arena Pharmaceuticals, Inc. - Product Pipeline Review - 2012” provides data on the Arena Pharmaceuticals, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Arena Pharmaceuticals, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Arena Pharmaceuticals, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
- Arena Pharmaceuticals, Inc. - Brief Arena Pharmaceuticals, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Arena Pharmaceuticals, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Arena Pharmaceuticals, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Arena Pharmaceuticals, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
- Evaluate Arena Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Arena Pharmaceuticals, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Arena Pharmaceuticals, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Arena Pharmaceuticals, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Arena Pharmaceuticals, Inc. and identify potential opportunities in those areas.
Current R&D Portfolio of Arena Pharmaceuticals, Inc.; Arena Pharmaceuticals, Inc. - Key Therapeutics; Arena Pharmaceuticals, Inc. - Pipeline Overview and Promising Molecules; Arena Pharmaceuticals, Inc. - News; Arena Pharmaceuticals, Inc. - Latest Updates; Arena Pharmaceuticals, Inc. - Pipeline; Arena Pharmaceuticals, Inc. - Discontinued/Dormant Projects
Arena Pharmaceuticals, Inc. Snapshot
Arena Pharmaceuticals, Inc. Overview
Key Information
Key Facts
Arena Pharmaceuticals, Inc. – Research and Development Overview
Key Therapeutic Areas
Arena Pharmaceuticals, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Arena Pharmaceuticals, Inc. – Pipeline Products Glance
Arena Pharmaceuticals, Inc. – Late Stage Pipeline
Registration Filed Products/Combination Treatment Modalities
Arena Pharmaceuticals, Inc. Clinical Stage Pipeline Products
Phase I Products/Combination Treatment Modalities
Arena Pharmaceuticals, Inc. – Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Arena Pharmaceuticals, Inc. – Drug Profiles
APD371
Product Description
Mechanism of Action
R&D Progress
APD811
Product Description
Mechanism of Action
R&D Progress
Lorcaserin
Product Description
Mechanism of Action
R&D Progress
Arena Pharmaceuticals, Inc. – Pipeline Analysis
Arena Pharmaceuticals, Inc. – Pipeline Products by Therapeutic Class
Arena Pharmaceuticals, Inc. – Pipeline Products By Target
Arena Pharmaceuticals, Inc. – Pipeline Products by Route of Administration
Arena Pharmaceuticals, Inc. – Pipeline Products By Mechanism of Action
Arena Pharmaceuticals, Inc. – Recent Pipeline Updates
Arena Pharmaceuticals, Inc. - Dormant Projects
Arena Pharmaceuticals, Inc. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
APD125
Arena Pharmaceuticals, Inc. – Company Statement
Arena Pharmaceuticals, Inc. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Arena Pharmaceuticals, Inc., Recent Developments
Arena Pharmaceuticals, Inc.- Press Release
May 10, 2012: Arena's Lorcaserin Receives Positive Vote From FDA Panel
Mar 26, 2012: Arena Announces EMA Acceptance Of Lorcaserin Marketing Authorization Application For Weight Control
Mar 02, 2012: Arena Pharmaceuticals Files European Marketing Authorization Application For Lorcaserin For Weight Control
Feb 01, 2012: Arena Pharmaceuticals Receives Notice From FDA Of Advisory Committee Meeting For Lorcaserin
Jan 10, 2012: FDA Accepts Resubmission Of Lorcaserin New Drug Application
Jan 03, 2012: Arena Submits Response To FDA's Complete Response Letter For Lorcaserin
Dec 22, 2009: Arena Pharmaceuticals Submits New Drug Application Of Lorcaserin To USFDA For Weight Loss
Jun 06, 2009: Arena Pharmaceuticals Announces Lorcaserin Data Demonstrating Highly Significant Categorical And Absolute Weight Loss And Improvements In Secondary Endpoints Associated With Cardiovascular Risk
Jun 01, 2009: Arena Pharmaceuticals Announces The Presentation Of Lorcaserin Phase 3 BLOOM Data At The American Diabetes Association's 69th Scientific Sessions
Financial Deals Landscape
Arena Pharmaceuticals, Inc., Deals Summary
Arena Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deal Details
Asset Transactions
Siegfried Sells Production Facility In Zofingen To Arena Pharma
Partnerships
Arena Pharma Extends Collaboration With Ortho-McNeil Pharma
Arena Pharma Expands Co-Marketing Agreement With Eisai For Lorcaserin
Arena Pharma Enters Into Co-Marketing Agreement With Eisai For Lorcaserin
Arena Pharma Enters Into Collaboration Agreement With Ortho-McNeil
Arena Pharma Expands Its Collaboration Agreement With Merck
Equity Offering
Arena Pharma Completes Public Offering Of Common Stock For $70 Million
Arena Pharma Completes Private Placement Of Common Stock For $16.5 Million
Arena Pharma Completes Private Placement Of Series D Preferred Stock For $16.5 Million
Arena Pharma Announces Private Placement Of Common Stock For $50 Million
Arena Pharma Completes Registered Direct Offering Of Common Stock For $18 Million
Arena Pharma Completes Registered Direct Offering Of Series C Preferred Stock For $18 Million
Arena Pharma Completes Registered Direct Offering For $60 Million
Arena Pharma Completes Private Placement Of Common Stock For $36 Million
Arena Pharma Completes Private Placement Of $25 Million
Arena Pharma Completes Public Offering Of $52 Million
Arena Pharma Completes Private Placement Of $15 Million
Arena Pharma Completes Public Offering Of $109.01 Million
Arena Pharma Completes Public Offering Of $174.7 Million
Arena Pharma Raises $8.3 Million Upon Exercise Of Warrants
Arena Pharma Completes Public Offering Of $179.77 Million
Arena Pharma Completes Public Offering Of $51.75 Million
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Arena Pharmaceuticals, Inc., Key Information
Arena Pharmaceuticals, Inc., Key Facts
Arena Pharmaceuticals, Inc. – Pipeline by Indication, 2012
Arena Pharmaceuticals, Inc. – Pipeline by Stage of Development, 2012
Arena Pharmaceuticals, Inc. – Monotherapy Products in Pipeline, 2012
Arena Pharmaceuticals, Inc. – Filed, 2012
Arena Pharmaceuticals, Inc. – Phase I, 2012
Arena Pharmaceuticals, Inc. – Pre-Clinical, 2012
Arena Pharmaceuticals, Inc. – Pipeline By Therapeutic Class, 2012
Arena Pharmaceuticals, Inc. - Pipeline By Target, 2012
Arena Pharmaceuticals, Inc. – Pipeline By Route of Administration, 2012
Arena Pharmaceuticals, Inc. – Pipeline Products By Mechanism of Action, 2012
Arena Pharmaceuticals, Inc. – Recent Pipeline Updates, 2012
Arena Pharmaceuticals, Inc. - Dormant Developmental Projects,2012
Arena Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2012
Arena Pharmaceuticals, Inc., Subsidiaries
Arena Pharmaceuticals, Inc., Deals Summary
Siegfried Sells Production Facility In Zofingen To Arena Pharma
Arena Pharma Extends Collaboration With Ortho-McNeil Pharma
Arena Pharma Expands Co-Marketing Agreement With Eisai For Lorcaserin
Arena Pharma Enters Into Co-Marketing Agreement With Eisai For Lorcaserin
Arena Pharma Enters Into Collaboration Agreement With Ortho-McNeil
Arena Pharma Expands Its Collaboration Agreement With Merck
Arena Pharma Completes Public Offering Of Common Stock For $70 Million
Arena Pharma Completes Private Placement Of Common Stock For $16.5 Million
Arena Pharma Completes Private Placement Of Series D Preferred Stock For $16.5 Million
Arena Pharma Announces Private Placement Of Common Stock For $50 Million
Arena Pharma Completes Registered Direct Offering Of Common Stock For $18 Million
Arena Pharma Completes Registered Direct Offering Of Series C Preferred Stock For $18 Million
Arena Pharma Completes Registered Direct Offering For $60 Million
Arena Pharma Completes Private Placement Of Common Stock For $36 Million
Arena Pharma Completes Private Placement Of $25 Million
Arena Pharma Completes Public Offering Of $52 Million
Arena Pharma Completes Private Placement Of $15 Million
Arena Pharma Completes Public Offering Of $109.01 Million
Arena Pharma Completes Public Offering Of $174.7 Million
Arena Pharma Raises $8.3 Million Upon Exercise Of Warrants
Arena Pharma Completes Public Offering Of $179.77 Million
Arena Pharma Completes Public Offering Of $51.75 Million
LIST OF FIGURES
Arena Pharmaceuticals, Inc. – Pipeline by Indication, 2012
Arena Pharmaceuticals, Inc. – Pipeline by Stage of Development, 2012
Arena Pharmaceuticals, Inc. – Monotherapy Products in Pipeline, 2012
Arena Pharmaceuticals, Inc. – Pipeline By Therapeutic Class, 2012
Arena Pharmaceuticals, Inc. - Pipeline By Target, 2012
Arena Pharmaceuticals, Inc. - Pipeline Products By Mechanism of Action, 2012
Arena Pharmaceuticals, Inc. Overview
Key Information
Key Facts
Arena Pharmaceuticals, Inc. – Research and Development Overview
Key Therapeutic Areas
Arena Pharmaceuticals, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Arena Pharmaceuticals, Inc. – Pipeline Products Glance
Arena Pharmaceuticals, Inc. – Late Stage Pipeline
Registration Filed Products/Combination Treatment Modalities
Arena Pharmaceuticals, Inc. Clinical Stage Pipeline Products
Phase I Products/Combination Treatment Modalities
Arena Pharmaceuticals, Inc. – Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Arena Pharmaceuticals, Inc. – Drug Profiles
APD371
Product Description
Mechanism of Action
R&D Progress
APD811
Product Description
Mechanism of Action
R&D Progress
Lorcaserin
Product Description
Mechanism of Action
R&D Progress
Arena Pharmaceuticals, Inc. – Pipeline Analysis
Arena Pharmaceuticals, Inc. – Pipeline Products by Therapeutic Class
Arena Pharmaceuticals, Inc. – Pipeline Products By Target
Arena Pharmaceuticals, Inc. – Pipeline Products by Route of Administration
Arena Pharmaceuticals, Inc. – Pipeline Products By Mechanism of Action
Arena Pharmaceuticals, Inc. – Recent Pipeline Updates
Arena Pharmaceuticals, Inc. - Dormant Projects
Arena Pharmaceuticals, Inc. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
APD125
Arena Pharmaceuticals, Inc. – Company Statement
Arena Pharmaceuticals, Inc. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Arena Pharmaceuticals, Inc., Recent Developments
Arena Pharmaceuticals, Inc.- Press Release
May 10, 2012: Arena's Lorcaserin Receives Positive Vote From FDA Panel
Mar 26, 2012: Arena Announces EMA Acceptance Of Lorcaserin Marketing Authorization Application For Weight Control
Mar 02, 2012: Arena Pharmaceuticals Files European Marketing Authorization Application For Lorcaserin For Weight Control
Feb 01, 2012: Arena Pharmaceuticals Receives Notice From FDA Of Advisory Committee Meeting For Lorcaserin
Jan 10, 2012: FDA Accepts Resubmission Of Lorcaserin New Drug Application
Jan 03, 2012: Arena Submits Response To FDA's Complete Response Letter For Lorcaserin
Dec 22, 2009: Arena Pharmaceuticals Submits New Drug Application Of Lorcaserin To USFDA For Weight Loss
Jun 06, 2009: Arena Pharmaceuticals Announces Lorcaserin Data Demonstrating Highly Significant Categorical And Absolute Weight Loss And Improvements In Secondary Endpoints Associated With Cardiovascular Risk
Jun 01, 2009: Arena Pharmaceuticals Announces The Presentation Of Lorcaserin Phase 3 BLOOM Data At The American Diabetes Association's 69th Scientific Sessions
Financial Deals Landscape
Arena Pharmaceuticals, Inc., Deals Summary
Arena Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deal Details
Asset Transactions
Siegfried Sells Production Facility In Zofingen To Arena Pharma
Partnerships
Arena Pharma Extends Collaboration With Ortho-McNeil Pharma
Arena Pharma Expands Co-Marketing Agreement With Eisai For Lorcaserin
Arena Pharma Enters Into Co-Marketing Agreement With Eisai For Lorcaserin
Arena Pharma Enters Into Collaboration Agreement With Ortho-McNeil
Arena Pharma Expands Its Collaboration Agreement With Merck
Equity Offering
Arena Pharma Completes Public Offering Of Common Stock For $70 Million
Arena Pharma Completes Private Placement Of Common Stock For $16.5 Million
Arena Pharma Completes Private Placement Of Series D Preferred Stock For $16.5 Million
Arena Pharma Announces Private Placement Of Common Stock For $50 Million
Arena Pharma Completes Registered Direct Offering Of Common Stock For $18 Million
Arena Pharma Completes Registered Direct Offering Of Series C Preferred Stock For $18 Million
Arena Pharma Completes Registered Direct Offering For $60 Million
Arena Pharma Completes Private Placement Of Common Stock For $36 Million
Arena Pharma Completes Private Placement Of $25 Million
Arena Pharma Completes Public Offering Of $52 Million
Arena Pharma Completes Private Placement Of $15 Million
Arena Pharma Completes Public Offering Of $109.01 Million
Arena Pharma Completes Public Offering Of $174.7 Million
Arena Pharma Raises $8.3 Million Upon Exercise Of Warrants
Arena Pharma Completes Public Offering Of $179.77 Million
Arena Pharma Completes Public Offering Of $51.75 Million
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Arena Pharmaceuticals, Inc., Key Information
Arena Pharmaceuticals, Inc., Key Facts
Arena Pharmaceuticals, Inc. – Pipeline by Indication, 2012
Arena Pharmaceuticals, Inc. – Pipeline by Stage of Development, 2012
Arena Pharmaceuticals, Inc. – Monotherapy Products in Pipeline, 2012
Arena Pharmaceuticals, Inc. – Filed, 2012
Arena Pharmaceuticals, Inc. – Phase I, 2012
Arena Pharmaceuticals, Inc. – Pre-Clinical, 2012
Arena Pharmaceuticals, Inc. – Pipeline By Therapeutic Class, 2012
Arena Pharmaceuticals, Inc. - Pipeline By Target, 2012
Arena Pharmaceuticals, Inc. – Pipeline By Route of Administration, 2012
Arena Pharmaceuticals, Inc. – Pipeline Products By Mechanism of Action, 2012
Arena Pharmaceuticals, Inc. – Recent Pipeline Updates, 2012
Arena Pharmaceuticals, Inc. - Dormant Developmental Projects,2012
Arena Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2012
Arena Pharmaceuticals, Inc., Subsidiaries
Arena Pharmaceuticals, Inc., Deals Summary
Siegfried Sells Production Facility In Zofingen To Arena Pharma
Arena Pharma Extends Collaboration With Ortho-McNeil Pharma
Arena Pharma Expands Co-Marketing Agreement With Eisai For Lorcaserin
Arena Pharma Enters Into Co-Marketing Agreement With Eisai For Lorcaserin
Arena Pharma Enters Into Collaboration Agreement With Ortho-McNeil
Arena Pharma Expands Its Collaboration Agreement With Merck
Arena Pharma Completes Public Offering Of Common Stock For $70 Million
Arena Pharma Completes Private Placement Of Common Stock For $16.5 Million
Arena Pharma Completes Private Placement Of Series D Preferred Stock For $16.5 Million
Arena Pharma Announces Private Placement Of Common Stock For $50 Million
Arena Pharma Completes Registered Direct Offering Of Common Stock For $18 Million
Arena Pharma Completes Registered Direct Offering Of Series C Preferred Stock For $18 Million
Arena Pharma Completes Registered Direct Offering For $60 Million
Arena Pharma Completes Private Placement Of Common Stock For $36 Million
Arena Pharma Completes Private Placement Of $25 Million
Arena Pharma Completes Public Offering Of $52 Million
Arena Pharma Completes Private Placement Of $15 Million
Arena Pharma Completes Public Offering Of $109.01 Million
Arena Pharma Completes Public Offering Of $174.7 Million
Arena Pharma Raises $8.3 Million Upon Exercise Of Warrants
Arena Pharma Completes Public Offering Of $179.77 Million
Arena Pharma Completes Public Offering Of $51.75 Million
LIST OF FIGURES
Arena Pharmaceuticals, Inc. – Pipeline by Indication, 2012
Arena Pharmaceuticals, Inc. – Pipeline by Stage of Development, 2012
Arena Pharmaceuticals, Inc. – Monotherapy Products in Pipeline, 2012
Arena Pharmaceuticals, Inc. – Pipeline By Therapeutic Class, 2012
Arena Pharmaceuticals, Inc. - Pipeline By Target, 2012
Arena Pharmaceuticals, Inc. - Pipeline Products By Mechanism of Action, 2012